van Hout B A, Simoons M L
Institute for Medical Technology Assessment, Erasmus University Rotterdam, Netherlands.
Eur Heart J. 1995 Nov;16 Suppl L:81-5. doi: 10.1093/eurheartj/16.suppl_l.81.
A cost effectiveness study is presented on the use of c7E3 in high risk patients undergoing percutaneous coronary angioplasty (PTCA). The results from the EPIC study have been combined with cost data from The Netherlands. The study took account of the number of survivors without ischaemic events, and the number with neither ischaemic events nor bleeding (both measured after 6 months). It is estimated that the initial costs of c7E3 and the additional costs due to the increased risk of bleeding are almost entirely counterbalanced by the savings, as a result of fewer myocardial infarctions and revascularizations. The additional costs per additional patient without ischaemic events are approximately DFL 5235. The additional costs per additional patient with neither ischaemic events nor bleeding are estimated at DFL 15,685. Both figures are less than the average for similar procedures without c7E3. Sensitivity analysis supports the conclusion that c7E3 treatment is efficient. However, cost effectiveness could be further improved if patients are carefully selected.
一项关于在接受经皮冠状动脉腔内血管成形术（PTCA）的高危患者中使用c7E3的成本效益研究。EPIC研究的结果已与来自荷兰的成本数据相结合。该研究考虑了无缺血事件的幸存者数量，以及既无缺血事件也无出血的患者数量（均在6个月后测量）。据估计，c7E3的初始成本以及因出血风险增加而产生的额外成本几乎完全被节省的费用所抵消，这是由于心肌梗死和血管重建术减少所致。每增加一名无缺血事件的患者的额外成本约为5235荷兰盾。每增加一名既无缺血事件也无出血的患者的额外成本估计为15685荷兰盾。这两个数字均低于未使用c7E3的类似手术的平均成本。敏感性分析支持c7E3治疗有效的结论。然而，如果仔细选择患者，成本效益可能会进一步提高。
